GTBP — GT Biopharma, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 109657 ·
Last close
$3.18
Market Cap
$5.74M
52W High
$21.62
52W Low
$0.58
ADV30
67,585
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — — — —
Mar 2026 0 — -2,848,000 -2,833,000 9,996,000 8,923,000 2,416,000
Dec 2025 0 — -5,595,000 -23,031,000 8,106,000 6,811,000 2,319,000
Sep 2025 0 — -3,382,000 8,299,000 4,321,000 2,528,000 1,321,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-13,180,000
Investing CF
$0
Financing CF
$19,739,000
CapEx
—
Dividends Paid
$-144,000
Buybacks
—
EPS Diluted TTM
$-10.11
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-726,837,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-29,065,000
Pretax Income TTM
$-47,734,000
Interest Exp TTM
$63,000
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -12,422,000 -28,354,000 8,106,000 2,319,000 5,787,000 -12,914,000
Dec 2024 0 -14,364,000 -13,162,000 4,232,000 5,902,000 -1,670,000 -12,904,000
Dec 2023 0 -13,576,000 -7,597,000 14,109,000 6,633,000 7,476,000 -8,852,000
Dec 2022 0 -21,257,000 -20,884,000 16,736,000 5,002,000 11,734,000 -15,217,000

TTM Snapshot

Revenues TTM
$-723,000
NetIncome TTM
$-33,496,000
OpCashFlow TTM
—
Assets (Latest)
$5,788,000
Forward EPS
$-10.80

Peers — same industry

TickerNameMarket CapLastDaily %
OTLC Oncotelic Therapeutics, Inc. $5.72M $0.01 —
INNPF INNOCAN PHARMA Corp $5.80M $1.29 —
AEON AEON Biopharma, Inc. $5.66M $0.11 —
INBP INTEGRATED BIOPHARMA INC $5.59M $0.18 —
FBLG FibroBiologics, Inc. $6.00M $0.90 —

News headlines (Yahoo Finance, 1h cache)

GT Biopharma Reports Third Quarter 2026 Financial Results
2026-11-16 12:00 · Yahoo
GT Biopharma Explores A New Combination Approach For Pancreatic Cancer
2026-11-10 11:20 · Yahoo
GT Biopharma Oral Presentation at the SITC 2026 Annual Meeting
2026-11-09 12:00 · Yahoo
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
2026-10-26 12:00 · Yahoo
EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
2026-09-16 11:30 · Yahoo
GT Biopharma Reports Second Quarter 2026 Financial Results
2026-08-14 12:00 · Yahoo
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
2026-06-01 11:31 · Yahoo
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types
2026-05-14 12:16 · Yahoo
GT Biopharma Reports First Quarter 2026 Financial Results
2026-05-15 12:00 · Yahoo
GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
2026-09-15 13:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.